Tag

Takeda

6 stories

Lilly Paid $1.26B to License Hanmi's GLP-2

Lilly's $75M upfront bet on Hanmi's once-monthly GLP-2 could reach $1.26B if sonefpeglutide survives FDA, and its main rival already stumbled.

Deals Apr 18, 2026

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy

UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.

Deals Apr 6, 2026

Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race

Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.

deals

Deals Apr 6, 2026

Takeda Files WARN for 634 US Cuts, 247 of Them at Cambridge HQ

Takeda filed a WARN notice to cut 634 US jobs, with 247 hitting its Cambridge headquarters — the largest concentration in the restructuring.

Deals Apr 6, 2026

Takeda Walks Away From $150M Denali Dementia Bet After 8 Years

Takeda returns frontotemporal dementia drug DNL593 to Denali after 8 years and $150M, citing strategy—not safety—days after Denali's FDA approval win.

Deals Apr 5, 2026

Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B

Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.